Moderna Makes Big Post-IPO Strides With Pipeline Update

Moderna Inc. (NASDAQ: MRNA) shares made a handy gain early Tuesday after the company announced updates to several of its immuno-oncology and rare disease programs and outlined its 2019–2020 corporate objectives. Overall, Moderna has 21 mRNA development candidates in its pipeline, with 11 programs now in clinical development. In terms of its program updates the firm detailed: OX40L (mRNA-2416): Based […]

Read more

Why Axsome Therapeutics Depression Study Is All Smiles

Axsome Therapeutics Inc. (NASDAQ: AXSM) shares absolutely exploded on Monday after the company announced that its midstage trial in patients with major depressive disorder (MDD) met its primary endpoint. Not only did the firm’s Phase 2 Ascend trial of AXS-05 in MDD meet the prespecified primary endpoint, but it also significantly improved symptoms of depression. AXS-05 demonstrated a highly statistically […]

Read more

Why DBV Technologies Is Changing Up Senior Leadership

DBV Technologies S.A. (NASDAQ: DBVT) shares made a handy gain on Thursday after the company announced that it would be making some changes in its senior leadership ahead of its anticipated resubmission of its Viaskin Peanut Biologics License Application (BLA). Following recent interactions with the U.S. Food and Drug Administration (FDA), global manufacturing industry leader Julie O’Neill has been engaged, […]

Read more

TCR2 Therapeutics Files for IPO

TCR2 Therapeutics has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering. No pricing details were mentioned in the filing, although the offering was valued up to $100 million, but this is normally just a placeholder. The company intends to list its shares on the Nasdaq under the symbol TCRR. The underwriters […]

Read more

Ra Pharmaceuticals Delivers on Midstage Muscle Study

Ra Pharmaceuticals Inc. (NASDAQ: RARX) shares jumped on Monday after the company announced positive midstage results for the treatment of generalized myasthenia gravis (gMG). Ultimately, the Phase 2 clinical trial evaluating zilucoplan achieved clinically meaningful and statistically significant reductions in both the primary and key secondary endpoints for both zilucoplan dose groups tested versus placebo at 12 weeks. Zilucoplan achieved […]

Read more

Catabasis Wins With Early-Stage Duchenne Muscular Dystrophy Study

Catabasis Pharmaceuticals Inc. (NASDAQ: CATB) shares made a handy gain on Tuesday after the company announced early stage data from its Duchenne muscular dystrophy (DMD) study. The company announced that data from the Phase 1 MoveDMD clinical trial of edasalonexent were published in the Journal of Neuromuscular Diseases. Overall edasalonexent was well tolerated in pediatric patients and the data demonstrated […]

Read more

3 Top Biotech Stocks to Buy Right Now

GlycoMimetics (NASDAQ: GLYC), Five Prime Therapeutics (NASDAQ: FPRX), and Neurocrine Biosciences (NASDAQ: NBIX) may not be household names, but they could be smart additions to biotech portfolios now. Read on to find out how upcoming news could spark interest in GlycoMimetics as soon as next week, a gastric cancer drug could move the needle at Five Prime Therapeutics, and two […]

Read more

Biotech ETFs Hoping This Post-Election Trend Doesn’t Repeat

This article was originally published on ETFTrends.com. Stocks rallied Wednesday, a day after one of the most contentious midterm elections in U.S. history. In Tuesday’s midterm elections, Democrats emerged with control of the House while Republicans maintained control of the Senate. Among the winning exchange traded funds Wednesday were biotechnology funds, including the SPDR S&P Biotech ETF (NYSEArca: XBI), which […]

Read more
1 2 3 4